1. Glabridin may serve as an anti-inflammatory agent in diabetes-related vascular dysfunction,through regulating the synthesis and activity of iNOS under high-glucose levels; may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells.
2. Glabridin may have potential as a chemopreventive agent against liver cancer metastasis, by inhibiting the invasion of human HCC cells.
3. Glabridin inhibits Plasmodium falciparum growth in vitro with an IC50 23.9±0.43 uM, it is suitable for developing antimalarial agent from a cheap and sustainable source.
4. Glabridin has not only the inhibition of melanogenesis but also the inhibition of inflammation in the skins.
5. Glabridin has antioxidative effects.
6. Glabridin and its derivatives exhibit varying degrees of estrogen receptor agonism and demonstrate growth-inhibitory actions on breast cancer cells.
7. Glabridin has a neuroprotective effect via modulation of multiple pathways associated with apoptosis.
1. Catalpalactone can inhibit dopamine biosynthesis by reducing tyrosine hydroxylase (TH) and aromatic-l-amino acid decarboxylase (AADC) activities and enhance L-DOPA- induced cytotoxiciy in PC12 cells.
2. Catalpalactone displays good cytotoxicity activities against two human tumor cell lines(MCF-7,BxPC3).
3. Catalpalactone exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced Epstein-Barr virus early antigen (EBV-EA) activation in Raji cells.
4. Catapalactone exhibits potent inhibitory effects on lipopolysaccharide-induced NO synthesis in RAW 264.7 cells , with IC50 values of 9.80 microM.
5. Catalpalactone exhibits high antitermitic activity.
1. Ginsenosides Rg3 suppressed swelling of oxazolone-induced mouse ear contact dermatitis.
2. Ginsenosides Rg3 induced differentiation of HL-60 cells into granulocytes and modulation of PKC isoform levels.
3. Ginsenosides Rg3 inhibited LPS-induced iNOS and cytokine expressions.
4. Ginsenosides Rg3 is a potential therapeutic modality for neurodegenerative diseases by inhibiting microglial activation.
1. Hirsutanonol shows antibiotic activity.
2. Hirsutanonol inhibits nitric oxide synthase.
1. Fingolimod hydrochloride is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS)， fingolimod hydrochloride is generally well tolerated but requires diligence in patient selection and monitoring. Additional information is needed regarding risk of infection, malignancy and rebound disease with long-term use of fingolimod.
2. The gels containing 0.50% fingolimod hydrochloride (FNGL) and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of atopic dermatitis (AD), the presence of colloidal oatmeal may provide additional benefits.
3. Fingolimod hydrochloride can suppress inflammatory reaction of injured blood vessels and lessen the stenosis of injured blood vessels by regulating cyclooxygenase 2 and prostaglandin E2 mRNA expression using sphingosine1-phosphate receptor 1.
4. Fingolimod hydrochloride , a pak1 activator, can inhibit astemizole-induced hypertrophy and cytotoxicity in H9c2 cells, suggests that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.